Drug intelligence / Profile preview

6-methylprednisolone + colchicine + indomethacin

Development stage
Preclinical
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

This is a combination of three small molecule drugs—6-methylprednisolone (a synthetic glucocorticoid corticosteroid), colchicine (an anti-inflammatory alkaloid), and indomethacin (a nonsteroidal anti-inflammatory drug, NSAID). Each component has a distinct mechanism of action: - 6-methylprednisolone acts as an agonist at the glucocorticoid receptor, suppressing inflammation and immune responses. - Colchicine disrupts microtubule polymerization by binding to tubulin, inhibiting neutrophil motility and activity, thereby reducing inflammation. - Indomethacin inhibits cyclooxygenase enzymes (COX-1 and COX-2), blocking prostaglandin synthesis responsible for pain, fever, and inflammation. This combination may be considered in severe or refractory inflammatory conditions such as acute gout or relapsing polychondritis when monotherapy is insufficient. However, combining these agents increases the risk of gastrointestinal toxicity and other adverse effects; such regimens should only be used under close medical supervision[1][2][5].

02

Targets

GR (Glucocorticoid receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TUBB (Tubulin (alpha and beta subunits))PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on 6-methylprednisolone + colchicine + indomethacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-methylprednisolone + colchicine + indomethacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call